Schwannoma in neurofibromatosis type 1: A pitfall for detecting malignancy by metabolic imaging

Skeletal Radiology

Volumn 42, Issue 9, 2013, Pages 1317-1322

  Ahlawat, Shivani ^a   Blakeley, Jaishri ^b   Montgomery, Elizabeth ^b   Subramaniam, Rathan M ^b   Belzberg, Allan ^b   Fayad, Laura M ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Malignant peripheral nerve sheath tumor; Neurofibroma; Neurofibromatosis type 1; Schwannoma

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DISEASE DURATION; GLIOMA; HISTOLOGY; HUMAN; KNEE PAIN; LEG DISEASE; LEG PAIN; MALE; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; NEURILEMOMA; NEUROFIBROMATOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PARESTHESIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SOFT TISSUE TUMOR; THIGH TUMOR; TUMOR LOCALIZATION;

EID: 84881100313     PISSN: 03642348     EISSN: 14322161     Source Type: Journal    
DOI: 10.1007/s00256-013-1626-3     Document Type: Article

References (29)

1. Jett K, Friedman JM. Clinical and genetic aspects of neurofibromatosis 1. Genet Med. 2010;12(1):1-11.
2. Walker L, Thompson D, Easton D, et al. A prospective study of neurofibromatosis type 1 cancer incidence in the UK. Br J Cancer. 2006;95(2):233-8.
3. Evan DG, Baser ME, McGaughran J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumor in neurofibromatosis 1. J Med Genet. 2002;39(5):311-4.
4. Warbey VS, Ferner RE, Dunn JT, Calonje M, O'Doherty MJ. FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1. Eur J Nucl Med Mol Imaging. 2009;36(5):754-7.
5. Wasa J, Nishida Y, Tsukushi S, Shido Y, Suguira H, Nakashima H, et al. MRI features in the differentiation of malignant peripheral nerve sheath tumors and neurofibromas. AJR Am J Roentgenol. 2010;194(6):1568-74.
6. Li CS, Huang GS, Wu HD, et al. Differentiation of soft tissue benign and malignant peripheral nerve sheath tumors with magnetic resonance imaging. Clin Imaging. 2008;32(2):121-7.
7. Matsumine A, Kusuzaki K, Nakamura T, et al. Differentiation between neurofibromas and malignant peripheral nerve sheath tumors in neurofibromatosis 1 evaluated by MRI. J Cancer Res Clin Oncol. 2009;135(7):891-900.
8. Fayad LM, Jacobs MA, Wang X, Carrino JA, Bluemke DA. Musculoskeletal tumors: how to use anatomic, functional and metabolic MR techniques. Radiology. 2012;265(2):340-56.
9. Subhawong TK, Wang X, Durand DJ, Jacobs MA, Carrino JA, Machado AJ, et al. Proton MR spectroscopy in metabolic assessment in musculoskeletal lesions. AJR Am J Roentgenol. 2012;198(1):162-72.
10. Nagata S, Nishimura H, Uchida M, Sakoda J, et al. Diffusion-weighted imaging of soft tissue tumors: usefulness of the apparent diffusion coefficient for differential diagnosis. Radiat Med. 2008;28(5):287-95.
11. Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM, Ilstrup DM. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer. 1986;57(10):2006-21.
12. Bredella M, Martin T, Francis H, et al. Value of PET in the assessment of patients with neurofibromatosis type 1. AJR Am J Roentgenol. 2007;189(4):928-35.
13. Ferner RE, Golding JF, Smith M, Calonie E, Jan W, Sanjayanatha V, et al. 18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1)-associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study. Ann Oncol. 2008;19(2):390-4.
14. Benz MR, Czernin J, Dry SM, et al. Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign. Cancer. 2010;116(2):451-8.
15. Honda E, Hayashi T, Goto S, et al. Two different spinal tumors (meningioma and schwannoma) with von Recklinghausen's disease in a case. No Shinkei Geka. 1990;18(5):463-8.
16. Watanabe M, Ishikawa N, Kameoka N, et al. Presacral Schwannoma in a patient with von Recklinghausen's disease: case report. Jpn J Gastroenterol Surg. 2002;25(4):436-9.
17. Feany MB, Fletcher CD. Nerve sheath tumours with hybrid features of neurofibroma and schwannoma: a conceptual challenge. Histopathology. 2000;36(5):473-4.
18. Harder A, Wesemann M, Hagel C, Schittenhelm J, et al. Hybrid neurofibroma/schwannoma is overrepresented among schwannomatosis and neurofibromatosis patients. Am J Surg Pathol. 2012;36(5):702-9.
19. Rodriguez FJ, Folpe AL, Giannini C, Perry A. Pathology of peripheral nerve sheath tumors: diagnostic overview and update on selected diagnostic problems. Acta Neuropathol. 2012;123(3):295-319.
20. Oka K, Yakushiji T, Sato H, Yorimitsu S, Hayashida Y, Yamashita Y, et al. Ability of diffusion-weighted imaging for the differential diagnosis between chronic expanding hematomas and malignant soft tissue tumors. J Magn Reson Imaging. 2008;28(5):1195-200.
21. Tamai K, Koyama T, Saga T, Morisawa N, Fujimoto K, Mikami Y, et al. The utility of diffusion-weighted MR imaging for differentiating uterine sarcomas from benign leiomyomas. Eur Radiol. 2008;18(4):723-30.
22. van Rijswijk CS, Kunz P, Hogendoorn PC, Taminiau AH, Doornbos J, Bloem JL. Diffusion-weighted MRI in the characterization of soft-tissue tumors. J Magn Reson Imaging. 2002;15(3):302-7.
23. Nagata S, Nishimura H, Uchida M, Sakoda J, Tonan T, Hiraoka K, et al. Diffusion-weighted imaging of soft tissue tumors: usefulness of the apparent diffusion coefficient for differential diagnosis. Radiat Med. 2008;26:287-95.
24. Einarsdottir H, Karlsson M, Wejde J, Bauer HC. Diffusion-weighted MRI of soft tissue tumours. Eur Radiol. 2004;14(6):959-63.
25. Genovese E, Cani A, Rizzo S, Angeretti MG, Leonardi A, Fugazzola C. Comparison between MRI with spin-echo echo-planar diffusion-weighted sequence (DWI) and histology in the diagnosis of soft-tissue tumours. Radiol Med. 2011;116(4):644-56.
26. Wang CK, Li CW, Hsieh TJ, Chien SH, Liew GC, Tsai KB. Characterization of bone and soft tissue tumors with in vivo 1H MR spectroscopy: initial results. Radiology. 2004;232(2):599-605.
27. Fayad LM, Barker PB, Jacobs MA, Eng J, Weber KL, Kulesza P, et al. Quantification of muscle choline concentrations by proton MR spectroscopy at 3 T: technical feasibility. AJR Am J Roentgenol. 2010;194(1):73-9.
28. Fayad LM, Wang X, Salibi N, et al. A feasibility study of quantitative molecular characterization of musculoskeletal lesions by proton MR spectroscopy at 3 T. AJR Am J Roentgenol. 2010;195(1):69-75.
29. Lee CW, Lee JH, Kim DH, Min HS, Park BK, et al. Proton magnetic resonance spectroscopy of musculoskeletal lesions at 3 T with metabolite quantification. Clin Imaging. 2010;34(1):47-52.